Meeting of the National Vaccine Advisory Committee, 17170 [2021-06692]
Download as PDF
<![CDATA[
17170
Federal Register / Vol. 86, No. 61 / Thursday, April 1, 2021 / Notices
technology to minimize the information
collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2021–06690 Filed 3–31–21; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Vaccine
Advisory Committee
Office of Infectious Disease and
HIV/AIDS Policy, Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that the National Vaccine Advisory
Committee (NVAC) will hold a virtual
meeting. The meeting will be open to
the public and public comment will be
heard during the meeting.
DATES: The meeting will be held June
16–17, 2021. The confirmed meeting
times and agenda will be posted on the
NVAC website at https://www.hhs.gov/
nvpo/nvac/meetings/ as soon
as they become available.
ADDRESSES: Instructions regarding
attending this meeting will be posted
online at: https://www.hhs.gov/nvpo/
nvac/meetings/ at least one
week prior to the meeting. Preregistration is required for those who
wish to attend the meeting or participate
in public comment. Please register at
https://www.hhs.gov/nvpo/nvac/
meetings/.
FOR FURTHER INFORMATION CONTACT: Ann
Aikin, Acting Designated Federal
Officer, at the Office of Infectious
Disease and HIV/AIDS Policy, U.S.
Department of Health and Human
Services, Mary E. Switzer Building,
Room L618, 330 C Street SW,
Washington, DC 20024. Email: nvac@
hhs.gov. Phone: 202–695–9742.
SUPPLEMENTARY INFORMATION: Pursuant
to Section 2101 of the Public Health
Service Act (42 U.S.C. 300aa–1), the
Secretary of HHS was mandated to
establish the National Vaccine Program
to achieve optimal prevention of human
infectious diseases through
immunization and to achieve optimal
prevention against adverse reactions to
vaccines. The NVAC was established to
provide advice and make
recommendations to the Director of the
National Vaccine Program on matters
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:02 Mar 31, 2021
Jkt 253001
related to the Program’s responsibilities.
The Assistant Secretary for Health
serves as Director of the National
Vaccine Program.
During this NVAC meeting, NVAC
will hear presentations on vaccine
safety, communication activities for
COVID–19 vaccines, and immunization
equity. Please note that agenda items are
subject to change, as priorities dictate.
Information on the final meeting agenda
will be posted prior to the meeting on
the NVAC website: https://www.hhs.gov/
nvpo/nvac/.
Members of the public will have the
opportunity to provide comment at the
NVAC meeting during the public
comment period designated on the
agenda. Public comments made during
the meeting will be limited to three
minutes per person to ensure time is
allotted for all those wishing to speak.
Individuals are also welcome to submit
written comments in advance. Written
comments should not exceed three
pages in length. Individuals submitting
comments should email their written
comments or their request to provide a
comment during the meeting to nvac@
hhs.gov at least five business days prior
to the meeting.
Ann Aikin,
Acting Designated Federal Official, Office of
the Assistant Secretary for Health.
[FR Doc. 2021–06692 Filed 3–31–21; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs using Urine or Oral Fluid
(Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT:
Anastasia Donovan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
SUMMARY:
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
2600 (voice); Anastasia.Donovan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: In
accordance with Section 9.19 of the
Mandatory Guidelines, a notice listing
all currently HHS-certified laboratories
and IITFs is published in the Federal
Register during the first week of each
month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
The Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
of the laboratories currently certified to
meet the standards of the Mandatory
Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020.
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Pub. L. 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
E:\FR\FM\01APN1.SGM
01APN1
]]>Agencies
[Federal Register Volume 86, Number 61 (Thursday, April 1, 2021)]
[Notices]
[Page 17170]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06692]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the National Vaccine Advisory Committee
AGENCY: Office of Infectious Disease and HIV/AIDS Policy, Office of the
Assistant Secretary for Health, Office of the Secretary, Department of
Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (HHS) is hereby giving notice
that the National Vaccine Advisory Committee (NVAC) will hold a virtual
meeting. The meeting will be open to the public and public comment will
be heard during the meeting.
DATES: The meeting will be held June 16-17, 2021. The confirmed meeting
times and agenda will be posted on the NVAC website at https://www.hhs.gov/nvpo/nvac/meetings/ as soon as they become
available.
ADDRESSES: Instructions regarding attending this meeting will be posted
online at: https://www.hhs.gov/nvpo/nvac/meetings/ at least
one week prior to the meeting. Pre-registration is required for those
who wish to attend the meeting or participate in public comment. Please
register at https://www.hhs.gov/nvpo/nvac/meetings/.
FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal
Officer, at the Office of Infectious Disease and HIV/AIDS Policy, U.S.
Department of Health and Human Services, Mary E. Switzer Building, Room
L618, 330 C Street SW, Washington, DC 20024. Email: [email protected].
Phone: 202-695-9742.
SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public
Health Service Act (42 U.S.C. 300aa-1), the Secretary of HHS was
mandated to establish the National Vaccine Program to achieve optimal
prevention of human infectious diseases through immunization and to
achieve optimal prevention against adverse reactions to vaccines. The
NVAC was established to provide advice and make recommendations to the
Director of the National Vaccine Program on matters related to the
Program's responsibilities. The Assistant Secretary for Health serves
as Director of the National Vaccine Program.
During this NVAC meeting, NVAC will hear presentations on vaccine
safety, communication activities for COVID-19 vaccines, and
immunization equity. Please note that agenda items are subject to
change, as priorities dictate. Information on the final meeting agenda
will be posted prior to the meeting on the NVAC website: https://www.hhs.gov/nvpo/nvac/.
Members of the public will have the opportunity to provide comment
at the NVAC meeting during the public comment period designated on the
agenda. Public comments made during the meeting will be limited to
three minutes per person to ensure time is allotted for all those
wishing to speak. Individuals are also welcome to submit written
comments in advance. Written comments should not exceed three pages in
length. Individuals submitting comments should email their written
comments or their request to provide a comment during the meeting to
[email protected] at least five business days prior to the meeting.
Ann Aikin,
Acting Designated Federal Official, Office of the Assistant Secretary
for Health.
[FR Doc. 2021-06692 Filed 3-31-21; 8:45 am]
BILLING CODE 4150-44-P
